… f Exploratory Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., 2-3, 5-chome,
Tokodai, Tsukuba, Ibaraki 300-26, Japan n Department of Pharmacology, Pharmacological …

The aim of this study was to elucidate the in vitro inhibitory potency of FK506 on production
of the inflammatory cytokines, tumour necrosis factor (TNF)‐α and interleukin (IL)‐1β, with a …

… FR255031-treated rat with arthritis showed intact Toluidine Blue staining or IIC immunostaining
of articular cartilage (e and f). Trocade-treated rat showed severe joint damage with loss …

The objective of this study was to investigate the therapeutic potential of FK506 and other
immunosuppressive agents for the treatment of rheumatoid arthritis (RA), focusing on the …

Objective and design: The anti-arthritic properties of FK506 were compared with methotrexate
(MTX) in established adjuvant-induced arthritis (AIA) in rats.¶Material: Female Lewis rats.¶…

FK506 (Tacrolimus) and cyclosporin A exert their immunosuppressive effects via a common
mechanism, calcineurin inhibition, after binding to intracellular proteins termed …

Objective and design:To determine the effect of FK506 (tacrolimus) on paw inflammation,
TNF-α expression in joint, and bone and cartilage destruction in type II collagen-induced …

OBJECTIVE: To investigate the effects of prophylactic and therapeutic treatments with FK506
(tacrolimus), an immunosuppressive drug that specifically inhibits T cell activation, and …

FK973, a new, substituted dihydrobenzoxazine (11-acetyl-8-carbamoyloxymethyl-4-formyl-14-oxa-1,11-diazatetracyclo[7.4.1.0
.0 10,12 ]tetradeca-2,4,6-trien-6,9-diyl diacetate), was …

The antitumor activity of recombinant human tumor necrosis factor (rTNF-α) was examined on
murine tumors in mice and in cultured cells in vitro. Mice were implanted intradermally with …